Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban

Assistance Publique - Hôpitaux de Paris159 enrolled

Overview

The study will compare the efficacy and safety of oral rivaroxaban and subcutaneous dalteparin in patients with cancer associated thrombosis. It is designed as a non-inferiority open label randomized multicenter trial with blinded adjudication of outcome events.

Patients with active cancer and symptomatic pulmonary embolism, proximal deep vein thrombosis, iliac or caval thrombosis will be randomly assigned to receive either dalteparin using the CLOT regimen or to oral rivaroxaban using the conventional dosage given in the Einstein studies. Experimental and control treatments will be given for three months. The main outcome at three month will include all symptomatic and incidentally discovered venous thromboembolic events including pulmonary embolism (either objectively confirmed and death due to pulmonary embolism), lower limb and upper limb deep vein thrombosis, iliac, caval and visceral thrombosis and any worsening of vascular obstruction which will be collected systematically at inclusion and at day 90. The safety end-points will consist of the rate of major bleedings and the composite of major and non-major but clinically significant bleedings at day 90. All outcome events will be blindly adjudicated by a central independent adjudication committee.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

159

Conditions

Neoplasm Venous Thromboembolism

Interventions

rivaroxabanDRUG

rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks

Low-molecular-weight heparinDRUG

dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years * Social security affiliation * Written informed consent * Solid active cancer, high grade lymphoma or myeloma treated with Immunomodulatory drugs (IMiDs) (thalidomide or lenalidomide). Active cancer is defined as the presence of measurable disease or ongoing (or planned) chemotherapy, radiotherapy or targeted therapy at inclusion. * Histologically or cytologically proven cancer. * Symptomatic venous thromboembolism objectively confirmed diagnosed because of symptoms or discovered incidentally * High-risk of recurrent Venous thromboembolism (VTE) defined by a score of 0 or ≥ 1, using the following criteria: female sex (+1), lung cancer (+1), breast cancer (-1) non metastatic tumor (-2), previous VTE (+1). Exclusion Criteria: * Exclusive adjuvant hormonal treatment with no measurable residual disease * Sub-segmental isolated pulmonary embolism (PE) without associated proximal DVT * Isolated distal deep vein thrombosis (DVT) of the legs * Isolated upper-extremity DVT or superior vena cava thrombosis * Isolated visceral thrombosis * Platelet count \< 50 000 G/L * Active bleeding * Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C * Hemostatic defect with contraindication to anticoagulant treatment at therapeutic dosage * Vena cava filter at inclusion * Fibrinolytic therapy within 3 days preceding inclusion * Creatinine clearance \< 30 ml/min according to Cockcroft-Gault formula * Previous heparin-induced thrombocytopenia * Anticoagulant treatment at curative dosage for more than 3 days before inclusion * Pregnancy or lack of effective contraceptive treatment for women of childbearing age * Treatment with both strong CYP3A4 and P-glycoprotein (PgP) inhibitors: protease inhibitors for HIV disease, systemic ketoconazole * Treatment with a strong CYP3A4 inducer: rifampicin, carbamazepine, phenytoin. * Life expectancy \< 3 months * Eastern Cooperative Oncology Group (ECOG) level 3 or 4

Locations (15)

CHU Amiens - Medecine vasculaire (003)

Amiens, France

CHU Angers - Medecin Interne (002)

Angers, France

Espace Artois Santé

Arras, France

Outcomes

Primary Outcomes

Symptomatic DVT

Recurrent VTE during the 3-month treatment period including all symptomatic DVT (lower limbs distal and proximal DVTs, iliac and caval thrombosis, visceral thrombosis and deep vein thrombosis of the arm)

Time frame: 3 months

Symptomatic PE

Recurrent VTE during the 3-month treatment period including symptomatic PE

Time frame: 3 months

Unsuspected PE and DVT

Recurrent VTE during the 3-month treatment period including clinically unsuspected PE and DVT discovered incidentally

Time frame: 3 months

Worsening of pulmonary vascular or venous obstruction

Recurrent VTE during the 3-month treatment period including worsening of pulmonary vascular obstruction or venous obstruction on the systematic examinations performed at the end of the 3-month treatment period

Time frame: 3 months

Secondary Outcomes

Major and clinically significant bleedings during the 3-month treatment period

Major bleeding is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and includes any bleeding resulting in death; symptomatic bleeding in a critical organ including intracranial, intra spinal, intraocular, retroperitoneal, intra articular and pericardial bleeding and muscle bleeding resulting in compartment syndrome; symptomatic bleeding resulting in a decrease in the hemoglobin concentration of at least 2g/dL or resulting in the transfusion of at least two packs of blood red cells.

Time frame: 3 months

Symptomatic recurrences of PE or DVT of the legs

excluding visceral thrombosis, upper extremity deep vein thrombosis and clinically unsuspected PE and DVT diagnosed incidentally

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.